Clinical Trials Browser

Waldenstrom Macroglobulinemia × ibrutinib × 1 year × Clear all

NCT04840602 2026-03-18

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Phase 2 Recruiting

92 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07474961 2026-03-16

BLOOD-dose

Phase 4 Not yet recruiting

400 enrolled

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT01804686 2026-03-12

CAN3001

Phase 3 Recruiting

700 enrolled

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03506373 2026-03-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT03620903 2025-12-05

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Phase 2 Active not recruiting

53 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT01479842 2025-10-15

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Phase 1 Active not recruiting

48 enrolled

Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Phase 1 Not yet recruiting

21 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT04273139 2025-07-30

Ibrutinib + Venetoclax in Untreated WM

Phase 2 Active not recruiting

45 enrolled 15 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT04062448 2025-05-25

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Phase 2 Completed

16 enrolled 14 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT04263480 2025-04-04

CZAR-1

Phase 2 Active not recruiting

99 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms